EQS-News: Rentschler Biopharma SE / Key word(s): Personnel Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board 07.12.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board Laupheim, Milford, MA, USA, and Stevenage, UK, December 07, 2023 – Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including Advanced Therapy ..read more

EQS-News: Formycon AG / Key word(s): Regulatory Approval Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis® 07.12.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // December 07, 2023   Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis® Munich, Amsterdam, Zug, Toronto – Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. jointly announce that Health Canada has granted the “Notice of Compliance” (NOC) for Ranopto®1 (Ranibizumab), a biosimilar to Lucen ..read more

Cosmo Pharmaceuticals N.V. / Key word(s): Bond Cosmo confirms full redemption in cash of €175m Convertible Bonds 06.12.2023 / 06:00 GMT/BST Dublin, Ireland – 06 December 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Unsecured Convertible Bonds due 2023 in cash. Upcoming Calendar of Events   Preliminary Results 2023 February 15, 2024 Full Year 2023 Results and Annual Report 2023 March 21, 2024 Ordinary Annual General Meeting 2024 May 24, 2024 About Cosmo Cosmo is a ph ..read more

New York, 12/06/2023 / 08:00, EST/EDT – EQS Newswire – Laxxon Medical NEW YORK, NY / ACCESSWIRE / December 6, 2023 / Laxxon Medical announced today its attendance at the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, connecting global industry leaders, emerging fast-growth companies and innovative technologies of the investment community. Representing Laxxon Medical at the J.P.Morgan Healthcare Conference i ..read more

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Miscellaneous Hello SDAX! SCHOTT Pharma reaches next milestone as a publicly listed company 06.12.2023 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Hello SDAX! SCHOTT Pharma reaches next milestone as a publicly listed company SCHOTT Pharma to join the 160 most important shares listed on the Frankfurt stock exchange as of December 15, 2023 SDAX inclusion underlines company value, business model and strategy   The shares of SCHOTT Pharma AG & Co. KGaA (the “Company”; WKN A3ENQ5, ISI ..read more

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec-partner Jingxin receives approval for EVT201 in China 06.12.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. EVT201 APPROVED BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (“NMPA”) AS A NOVEL SHORT-TERM TREATMENT OF INSOMNIA EVOTEC’S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD (“JINGXIN”) WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA   Hamburg, Germany, 06 December 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE ..read more

EQS-News: Carbios SA / Key word(s): Personnel New appointment to Carbios' Executive Committee to secure rapid growth of its organization and operations 06.12.2023 / 06:45 CET/CEST The issuer is solely responsible for the content of this announcement. New appointment to Carbios’ Executive Committee to secure rapid growth of its organization and operations  Sophie BALMARY is appointed Director of Human Resources and Legal Affairs, and member of the Executive Committee Clermont-Ferrand (France), 6 December 2023 (06:45 CET). Carbios, (Euronext Growth Paris: ALCRB), a pioneer in the deve ..read more

Relief Therapeutics Holding SA / Key word(s): Miscellaneous 05-Dec-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth GENEVA (DEC. 5, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, t ..read more

Fresenius SE & Co. KGaA / Key word(s): Dividend Fresenius SE & Co. KGaA: Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023 05-Dec-2023 / 21:29 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective ..read more

Issuer: Mainz BioMed N.V. / Key word(s): Study results 05.12.2023 / 15:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers Groundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82%   Results Exceed those from the Company’s European ColoFuture Clinical Study of the Same Design   ColoFuture and eAArly DETECT Studies Support Inclusion of a Portfolio of Novel mRNA ..read more